The authors found that advanced glycosylation end product–specific receptor (AGER) contributed to MRTX1133 resistance in PDAC through modulation of macropinocytosis and glutathione synthesis using patient-derived xenografts and orthotopic and genetically engineered mouse models.
[Science Translational Medicine]